Anthony J. Frew

Anthony J. Frew

Auto-generated profile, based on publicly available information

Anthony J. Frew

Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AFAnthony J. Frew
Anthony J. Frew

22 May 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
AFAnthony J. Frew
Anthony J. Frew
A 28-year-old man presents with allergic rhinitis, primarily due to grass pollen, that has not previously responded to antihistamines and nasal sprays. A trial of sublingual immunotherapy is recommended. Sublingual immunotherapy is more convenient than injection immunotherapy. However, only one agent, which is specific for grass-pollen allergies, has been approved for clinical use in some European countries. The Food and Drug Administration has not approved any agent for sublingual immunotherapy.

23 April 2020 in Allergy
Verified
Journal Article
Open access
PDF file
OPOliver Pfaar
Oliver Pfaar
IAIoana Agache
Ioana Agache
KBKarl‐Christian Bergmann
Karl‐Christian Bergmann
CBCarsten Bindslev‐Jensen
Carsten Bindslev‐Jensen
JBJean Bousquet
Jean Bousquet
AFAnthony J. Frew
Anthony J. Frew
The placebo (Latin “I will please”) effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients’ expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials.


1 December 2003
Verified
Journal Article
Closed access
SHStephen T Holgate
Stephen T Holgate
TSThomas Sandström
Thomas Sandström
AFAnthony J Frew
Anthony J Frew
NSNikolai Stenfors
Nikolai Stenfors
CNCharlotta Nördenhall
Charlotta Nördenhall
MSMargaretha Söderberg
Margaretha Söderberg

11 April 2011 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AFAnthony Frew
Anthony Frew